AbbVie jumped from No. 5 to No. 3 and AstraZeneca eked past GSK with a bump in profits. Here’s the top 10 list:
1. Johnson & Johnson: $93.8 billion
2. Pfizer: $81.3 billion
3. Roche: $62.8 billion
4. AbbVie: $56.2 billion
5. Novartis: $52.9 billion
6. Merck: $48.7 billion
7. Bristol-Myers Squibb: $46.4 billion
8. Sanofi: $39.2 billion
9. AstraZeneca: $37.4 billion
10. GSK: $34.1 billion
Note: These drug companies are ranked by total revenue and do not exclusively include pharmaceutical profits.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.